ArticleBlood cancer journal2013
Lessons from next-generation sequencing analysis in hematological malignancies.
Article in Blood cancer journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Comparison of Optical Genome Mapping With Conventional Diagnostic Methods for Structural Variant Detection in Hematologic Malignancies.Annals of laboratory medicine · 2024Article
- Article
- Article
- The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications.International journal of molecular sciences · 2021Review
- Article
- Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.Cancers · 2021Review
- When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis.Journal of clinical medicine · 2021Review
- Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.Scientific reports · 2020Article
- Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant.HemaSphere · 2020Article
- Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention.Frontiers in pediatrics · 2019Review
- Unravelling the genomic landscape of leukemia using NGS techniques: the challenge remains.Blood research · 2017Article
- Therapy-related myeloid neoplasms - what have we learned so far?World journal of stem cells · 2016Review
- Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.Pediatric blood & cancer · 2016Article
- Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.Oncotarget · 2016Review
- Current Role of Genetics in Hematologic Malignancies.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Review
- Pharmacogenetics of cancer therapy: breakthroughs from beyond?Future science OA · 2015Review
- Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.Leukemia · 2015Article
- Emerging technologies in paediatric leukaemia.Translational pediatrics · 2015Review
- Cancer stem cells in haematological malignancies.Contemporary oncology (Poznan, Poland) · 2015Review
- Next-generation sequencing technologies: breaking the sound barrier of human genetics.Mutagenesis · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Next-generation sequencing has led to a revolution in the study of hematological malignancies with a substantial number of publications and discoveries in the last few years. Significant discoveries associated with disease diagnosis, risk stratification, clonal evolution and therapeutic intervention have been generated by this powerful technology. As part of the post-genomic era, sequencing analysis will likely become part of routine clinical testing and the challenge will ultimately be successfully transitioning from gene discovery to preventive and therapeutic intervention as part of individualized medicine strategies. In this report, we review recent advances in the understanding of hematological malignancies derived through genome-wide sequence analysis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.